These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15383195)

  • 21. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 24. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
    Berger A; Lord C; Corey-Lisle PK; Williams GR; Oster G
    Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".
    Nowrousian MR
    Oncologist; 2006 May; 11(5):535-6; author reply 536-7. PubMed ID: 16720859
    [No Abstract]   [Full Text] [Related]  

  • 28. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 30. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].
    Remón C; Quirós P; Fernández Marchena D; Hernández Romero M; del Castillo R; Fernández Ruiz E
    Nefrologia; 2005; 25(2):170-7. PubMed ID: 15912654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.